Roche Pharmaceutical Development and Sales Overview

Quarterly sales performance: COVID-19 sales coming down 15% 13% 14%* 12% 11% 9% 9% 10% 7% 7% 7% 6% 6% 6% 6% 6% 8% 8% 7% 5% 4% 6% 5% 5% 4% 4% 1% 3% 3% 3% 0% 1% 0% -5% -10% -15% AHR¹ impact -4% COVID-19 impact -6% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 15 15 15 15 16 16 16 16 17 17 17 17 18 18 18 18 19 19 19 19 20 20 20 20 21 21 21 21 22 22 22 Growth rates at CER (Constant Exchange Rates); * Q2 2020 sales severely impacted by COVID-19 pandemic onset; 1AHR: Avastin, Herceptin, Rituxan/MabThera Roche 8

View entire presentation